OSE Immunotherapeutics SA announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was EUR 8.975 million compared to EUR 5.849 million a year ago. Operating loss was EUR 11.580 million compared to EUR 7.085 million a year ago. Net loss was EUR 11.488 million compared to EUR 3.114 million a year ago. Basic loss per share from continuing operations was EUR 0.64 compared to EUR 0.21 a year ago.